entertainment -WSS

entertainment

author：comprehensive 2025-09-30 12:16:48 - browse：51974

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Removing probiotics from the NICU could threaten preemies' health

leisure time

WSS

Why does health care cost so much? A reading guide

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

More doctors should go into startup world

Element Biosciences CEO lays out genome sequencing strategy

Close Medicare's dangerous gaps in addiction treatment coverage

The new shift in health care is toward less care

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

STAT Executive Editor Rick Berke on STAT's 8th birthday

Medical leaders decry Supreme Court decision on affirmative action

Biotech incubator Curie.Bio graduates its first startup

How one medical school became remarkably diverse

FTC falls short on scrutinizing hospital mergers, study says

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Orangutan used medicinal plant to treat wound, first time ever seen

In age of alternative facts, a scholarly course on calling out crap

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

entertainment

Bird flu outbreak in cows is latest avian flu curveball

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Just how powerful is the placebo effect?

HPV cancer vaccine study demonstrates efficacy

Diversify hospital leadership teams to protect BIPOC patient health

Diversify hospital leadership teams to protect BIPOC patient health

leisure time

leisure time

leisure time

focus